Results 151 to 160 of about 27,075 (224)

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status. [PDF]

Int J Urol
Nukaya T, Naiki T, Watanabe H, Nakane K, Inamoto T, Yasui T, Koie T, Takahara K.   +7 more
europepmc   +1 more source

XYL-1 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Suppressing the SCD1/BRCA1 Signaling Pathway. [PDF]

Molecules
Yang Y, Huang L, Du Y, Zhu Q, Dai L, Qian B.   +5 more
europepmc   +1 more source

PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. [PDF]

Cell Rep Med
Lin L, Moradi N, Lähdeniemi IA, Laitinen HK, Alsaed B, Lahtinen L, Lopez T, Jansouz S, Knott A, Soroko KM, Ilonen I, Gokhale PC, Jänne PA, Haikala HM.   +13 more
europepmc   +1 more source

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report. [PDF]

Gynecol Oncol Rep
Liu C, Abozenah Y, Rutherford TJ, Andikyan V, Kohut A, Anderson ML.   +5 more
europepmc   +1 more source

MicroRNA320e Augments the Synthetic Lethality of Olaparib by Regulating the PI3K-AKT-mTOR Pathway. [PDF]

Oncol Res
Zheng W, Meng Q, Deng Y, Liu R, Bai S, Jia L, Wang J, Bai H.   +7 more
europepmc   +1 more source

Niraparib en el tratamiento del cáncer de ovario. Eficacia y seguridad relativas de niraparib y olaparib: comparaciones indirectas.

, 2018
Se evalúa la eficacia y seguridad de niraparib como tratamiento para el cáncer de ovario epitelial seroso, de las trompas de Falopio o peritoneal primario, de alto grado, recidivado, sensible al platino, a través de una revisión rápida y una comparación ...
Alfaro Lara, Eva R.
core  

PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]

Front Cell Dev Biol
Ouhajjou A, Mazouji O, Nejjari C, Incitti R, Mansour H.   +4 more
europepmc   +1 more source

BCLX_L blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. [PDF]

Signal Transduct Target Ther
Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH.   +25 more
europepmc   +1 more source

Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies. [PDF]

Int J Mol Sci
Elesnawy M, Masood E, Naik A.
europepmc   +1 more source

Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants. [PDF]

Int J Urol
Yasuda Y, Yoshida S, Yonese I, Sano Y, Matsumoto S, Urasaki T, Tamiya T, Tanaka H, Ito M, Miura Y, Numao N, Matsuoka Y, Koga F, Yonese J, Fujii Y.   +14 more
europepmc   +1 more source